Glenmark bags USFDA nod for Metronidazole Vaginal Gel

Written by Ruchika Sharma Published On 2022-01-28T11:12:59+05:30 | Updated On 28 Jan 2022 11:12 AM IST

Glenmark bags USFDA nod for Metronidazole Vaginal Gel

Mumbai: Drug maker, Glenmark Pharmaceuticals Inc., USA has received final approval from the United States Food & Drug Administration (USFDA) for Metronidazole Vaginal Gel, 0.75%.

The product is a generic version of MetroGel-Vaginal Gel, 0.75%, of Bausch Health US, LLC.

According to IQVIA sales data for the 12 month period ending November 2021, the MetroGel- Vaginal Gel, 0.75% market achieved annual sales of approximately $60.4 million*.

Glenmark's current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA's pending approval with the U.S. FDA.

In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharmaceuticals Limited is a global research-led pharmaceutical company with presence across generics, specialty and OTC businesses and with operations in over 50 countries.

Glenmark's key therapy focus areas globally are respiratory, dermatology and oncology. The company has been listed on the Dow Jones Sustainability Index (DJSI), under the category of emerging markets for four consecutive years in a row; most recently in 2021.

glenmarkglenmark newsmetronidazole vaginal gelmetrogel-vaginalusfda

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751